RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients

Phase 4 Completed 32 enrolled Abnoba GmbH

RandomizedParallel-groupOpen-labelSupportive care

Summary

Evaluation of safety and efficacy of a standardized mistletoe extract (abnobaVISCUM® Quercus, aVQ) in patients with gastric cancer receiving oral chemotherapy.

Timeline

Start: 2006-03
Primary completion: 2008-04
Completion: 2008-04

Publications

Results Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med. 2012 Oct 3;12:172. doi: 10.1186/1472-6882-12-172.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	abnobaVISCUM® Quercus	Unknown	0.02 mg	Subcutaneous
Subject	abnobaVISCUM® Quercus	Unknown	0.2 mg	Subcutaneous
Subject	abnobaVISCUM® Quercus	Unknown	2 mg	Subcutaneous
Subject	abnobaVISCUM® Quercus	Unknown	20 mg	Subcutaneous
Background	doxifluridine	Small molecule	600 mg	Oral
Background	doxifluridine	Small molecule	900 mg	Oral

RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients

Summary

Timeline

Publications

Drugs

Indications